Biomarker ID | 1440 |
PMID | 24909936 |
Year | 2014 |
Biomarker | MUC1 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Increased with Increased mortality |
Odds Ratio/Hazard Ratio/Relative Risk | Mortality Rate Ratios: MRR: 2.51 (95% CI 1.14–5.54) |
Effect on Pathways | Pathways include: Termination of O-glycan biosynthesis, Interleukin-11 pathway, O-linked glycosylation of mucins, Post-translational protein modification, Protein metabolism |
Experiment | PCa Specific Mortality Vs No Mortality |
Type of Biomarker | Prognostic |
Cohort | Subjects were identified from three Australian epidemiological studies. Men who had died of their disease, “cases†(N = 83), were matched to “referents†(N = 232), those who had not died of prostate cancer, using incidence density sampling. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.02 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |